Literature DB >> 1673592

Vecuronium neuromuscular blockade at the adductor muscles of the larynx and adductor pollicis.

F Donati1, C Meistelman, B Plaud.   

Abstract

The differences between neuromuscular blockade of the adductor muscles of the vocal cords and the adductor pollicis were examined in 20 adult women anesthetized with fentanyl and propofol. Vecuronium 0.04 or 0.07 mg/kg was given as a single bolus by random allocation. The force of contraction of the adductor pollicis was recorded. Laryngeal response was measured as pressure changes in the cuff of the tracheal tube positioned between the vocal cords. Train-of-four stimulation was applied to the recurrent laryngeal nerve at the notch of the thyroid cartilage and to the ulnar nerve at the wrist. Neuromuscular blockade had a faster onset, was less intense, and recovered more rapidly at the vocal cords. With 0.04 mg/kg, maximum blockade of first twitch (T1) was 55 +/- 8 (mean +/- standard error of the mean [SEM]) and 88 +/- 4% at the vocal cords and the adductor pollicis, respectively (P = 0.006). Onset time was 3.3 +/- 0.1 and 5.7 +/- 0.2 min, respectively (P = 0.000001), and time to 90% T1 recovery was 11.3 +/- 1.6 and 26.1 +/- 1.8 min, respectively (P = 0.001). With 0.07 mg/kg, onset time was unchanged; maximum blockade was more intense, being 88 +/- 4 and 98 +/- 1%, respectively (P = 0.04 between muscles); and time to 90% T1 recovery was 23.3 +/- 1.8 min at the vocal cords versus 40.3 +/- 2.9 min at the adductor pollicis (P = 0.001). Approximately 1.73 times as much vecuronium was required at the larynx compared with the dose required at the adductor pollicis for the same intensity of blockade.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1673592     DOI: 10.1097/00000542-199105000-00006

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  19 in total

1.  Posttetanic count revisited: are measurements more reliable using the TOF-Watch accelerographic peripheral nerve stimulator?

Authors:  Robert D Vincent; Russell C Brockwell; Michael C Moreno; Shannon L Adkins
Journal:  J Clin Monit Comput       Date:  2004-02       Impact factor: 2.502

Review 2.  Muscle relaxant use during intraoperative neurophysiologic monitoring.

Authors:  Tod B Sloan
Journal:  J Clin Monit Comput       Date:  2012-09-27       Impact factor: 2.502

3.  Why all muscles are not alike.

Authors:  R J Storella
Journal:  Can J Anaesth       Date:  1996-06       Impact factor: 5.063

Review 4.  Neuromuscular transmission and its pharmacological blockade. Part 3: Continuous infusion of relaxants and reversal and monitoring of relaxation.

Authors:  L H Booij
Journal:  Pharm World Sci       Date:  1997-02

5.  Duration of succinylcholine and vecuronium blockade but not potency correlates with the ratio of endplate size to fibre size in seven muscles in the goat.

Authors:  C Ibebunjo; C B Srikant; F Donati
Journal:  Can J Anaesth       Date:  1996-05       Impact factor: 5.063

6.  Randomized Clinical Trial of Moderate Versus Deep Neuromuscular Block for Low-Pressure Pneumoperitoneum During Laparoscopic Cholecystectomy.

Authors:  Bon-Wook Koo; Ah-Young Oh; Kwang-Suk Seo; Ji-Won Han; Ho-Seong Han; Yoo-Seok Yoon
Journal:  World J Surg       Date:  2016-12       Impact factor: 3.352

7.  Evaluation of cisatracurium, a new neuromuscular blocking agent, for tracheal intubation.

Authors:  L S Bluestein; L W Stinson; R L Lennon; S N Quessy; R M Wilson
Journal:  Can J Anaesth       Date:  1996-09       Impact factor: 5.063

8.  Nitrous oxide potentiates vecuronium neuromuscular blockade in humans.

Authors:  P Fiset; P Balendran; D R Bevan; F Donati
Journal:  Can J Anaesth       Date:  1991-10       Impact factor: 5.063

9.  How much relaxation?

Authors:  D R Bevan
Journal:  Can J Anaesth       Date:  1995-02       Impact factor: 5.063

10.  Different priming techniques, including mivacurium, accelerate the onset of rocuronium.

Authors:  M Naguib
Journal:  Can J Anaesth       Date:  1994-10       Impact factor: 5.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.